Generics [UK] Ltd t/a Mylan v Yeda Research and Development Company Ltd and Another
Jurisdiction | England & Wales |
Judge | Lord Justice Floyd,Lord Justice Kitchin,Lord Justice Moses,Sir Robin Jacob,Lord Justice Etherton,Lord Justice Ward |
Judgment Date | 29 July 2013 |
Neutral Citation | [2013] EWCA Civ 925,[2012] EWCA Civ 726 |
Docket Number | Case No: A3/2012/2136,Case No: A3/2011/3284 |
Court | Court of Appeal (Civil Division) |
Date | 29 July 2013 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
31 cases
-
Gilead Sciences Inc. (a company registered in the US State of Delaware) v Nucana Plc
...I accept this too. I dealt with it in Sandoz at [63] – [69], primarily by reference to what Floyd LJ said in Generics v Yeda [2013] EWCA Civ 925 at [64]–[65]. iii) A technical contribution must be of some, even if low, real significance. Disclosing a uselessly low degree of activity as a c......
-
Re Boehringer Ingelheim Pharma GmbH & Company Kg & Patents Acts
...in the courts of the neighbouring jurisdiction. (See, e.g., Generics (UK) Ltd (t/a Mylan) v. Yeda Research & Development Co. Ltd [2013] EWCA Civ. 925 and Idenix Pharmaceuticals Inc. v. Gilead Sciences Inc. [2016] EWCA Civ. 1089). It applies where a development may not be obvious but where......
-
Pfizer Ltd v Glaxosmithkline Biologicals S.A (a company incorporated under the laws of Belgium)
...by Court of Appeal in Sandoz & Teva v BMS [2023] EWCA Civ 472, citing the explanation given by Floyd LJ in Generics v Yeda [2013] EWCA Civ 925 at [39] as part of their consideration of the case law. “39. As with any consideration of obviousness, the technical results or effects must be......
-
Teva Pharmaceutical Industries Ltd v Novartis AG
...will not be found invalid as an arbitrary selection, whether for lack of inventive step, see for example Generics (UK) Ltd v Yeda Research & Development Co Ltd [2013] EWCA Civ 925 or for insufficiency, see for example Idenix Pharmaceuticals Inc v Gilead Sciences Inc [2016] EWCA Civ 1089. Ho......
Request a trial to view additional results
5 firm's commentaries
-
IP Bulletin - Autumn 2012
...advisers or patent attorneys). Generics (UK) Ltd v Yeda Research & Development Co Ltd & Teva Pharmaceutical Industries Ltd [2012] EWCA Civ 726 http://www.bailii.org/ew/cases/EWCA/Civ/2012/726.html Generics (UK) Ltd ("Generics") sought a declaration of non-infringement and revocation......
-
Validity - Annual Patents Review 2017
...Company Limited & Anr [2017] EWHC 2629 (Pat) (26 October 2017) Arnold J Generics (UK) Ltd v Yeda Research and Development Co Ltd [2013] EWCA Civ 925 Idenix Pharmaceuticals Inc v Gilead Sciences Inc [2016] EWCA Civ 1089 Varian Medical Systems International AG v Elekta Limited & Anr [......
-
Intellectual Property Bulletin - Winter 2013
...be used to challenge the validity of a patent. Generics (UK) Ltd (trading as Mylan) v Yeda Research and Development Co Ltd and another [2013] EWCA Civ 925, 29 July The analysis of whether the invention made a technical contribution involved a review of clinical trials data in this case. In ......
-
Using Post-Priority Evidence To Demonstrate Lack Of Invention
...Generics [UK] Limited t/a Mylan ("Mylan") v Yeda Research & Development Co Ltd ("Yeda") & Teva Pharmaceuticals Industries Ltd [2013] EWCA Civ 925. It concerns Yeda's patent for a synthetic copolymer known as copolymer-1. Mylan had sought revocation of the patent and a declaration of......
Request a trial to view additional results